Revolution Medicines

Revolution Medicines

Yahoo Finance • 5 days ago

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According... Full story

Yahoo Finance • 11 days ago

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

AIM ImmunoTech Inc. Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months... Full story

Yahoo Finance • 17 days ago

Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift

Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (ne... Full story

Yahoo Finance • 28 days ago

Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?

Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have receiv... Full story

Yahoo Finance • 30 days ago

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Revolution Medicines, Inc. Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines... Full story

Yahoo Finance • last month

Patients with the deadliest cancer finally have something that works

For decades, a pancreatic cancer diagnosis came with almost no good options. The disease is usually caught late, spreads fast, and resists most treatments. Patients and their families were often left with months, not years. That grim pic... Full story

Yahoo Finance • last month

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer

Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque.... Full story

Yahoo Finance • last month

Bloomberg 500 (B500) Index Adds Ten Securities Following September Reconstitution

NEW YORK, Aug. 26, 2026 /PRNewswire/ -- Bloomberg Indices announced the following changes to the Bloomberg 500 (B500) Index, effective prior to the open of trading on Thursday, September 10, 2026, to coincide with the September reconstitut... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Fall Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index falling 1.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • last month

Should JPMorgan BetaBuilders U.S. Mid Cap Equity ETF (BBMC) Be on Your Investing Radar?

The JPMorgan BetaBuilders U.S. Mid Cap Equity ETF (BBMC) was launched on April 14, 2020, and is a passively managed exchange traded fund designed to offer broad exposure to the Mid Cap Blend segment of the US equity market. The fund is sp... Full story

Yahoo Finance • last month

Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?

Imagine running a fund for 30 years, including during the aftermath of the dot-com bubble bursting and the financial crisis of 2008, without a single losing year. If you're Stanley Druckenmiller, no imagination is required. He achieved thi... Full story

Yahoo Finance • last month

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

Revolution Medicines (RVMD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Corporate Affairs - Ryan AsayChairman and Chief Executive Officer - Mark GoldsmithChief Development Officer - Alan San... Full story

Yahoo Finance • 2 months ago

Why Revolution Medicines May Be Big Pharma’s Next Takeover Target

Quick Read RVMD has surged 492% over one year on daraxonrasib's landmark pancreatic cancer data showing 13.2 versus 6.7 months median overall survival. MRK ranks as the most likely acquirer, with Keytruda's patent cliff mounting pressure... Full story

Yahoo Finance • 2 months ago

Revolution Medicines (RVMD) Is Up 6.2% After BeOne-Funded Phase 3 RAS(ON) Deal - Has The Bull Case Changed?

In early August 2026, BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors, alongside a regional licensing deal granti... Full story

Yahoo Finance • 2 months ago

Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48%... Full story

Yahoo Finance • 2 months ago

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines. Continue Reading... Full story

Yahoo Finance • 2 months ago

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock

Shares of biotechnology company Revolution Medicines (NASDAQ: RVMD) have surged more than 134% so far this year. Billionaire investor Stanley Druckenmiller's Duquesne Family Office drew attention to the stock by buying 316,000 shares of Re... Full story

Yahoo Finance • 2 months ago

Vanguard VONG vs VBK: Is a Small Cap ETF the Better Buy Over a Large Cap Fund in 2026?

Vanguard Russell 1000 Growth ETF (NASDAQ:VONG) offers heavy concentration in mega-cap technology leaders, while Vanguard Morningstar Small-Cap Growth ETF (NYSEMKT:VBK) provides a diversified mix of smaller growth companies at a slightly lo... Full story

Yahoo Finance • 2 months ago

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will... Full story